Publications by Vivi Ann Flørenes
106 publications found
Original articles
AXL inhibition improves BRAF-targeted treatment in melanoma
Sci Rep, 12 (1), 5076
DOI 10.1038/s41598-022-09078-z, PubMed 35332208
Targeting Telomerase with an HLA Class II-Restricted TCR for Cancer Immunotherapy
Mol Ther, 29 (3), 1199-1213
DOI 10.1016/j.ymthe.2020.11.019, PubMed 33212301
Death domain-associated protein (DAXX) expression is associated with poor survival in metastatic high-grade serous carcinoma
Virchows Arch, 477 (6), 857-864
DOI 10.1007/s00428-020-02842-4, PubMed 32533344
Molecularly matched therapy in the context of sensitivity, resistance, and safety; patient outcomes in end-stage cancer - the MetAction study
Acta Oncol, 59 (7), 733-740
DOI 10.1080/0284186X.2020.1742377, PubMed 32208873
Soluble AXL as a marker of disease progression and survival in melanoma
PLoS One, 15 (1), e0227187
DOI 10.1371/journal.pone.0227187, PubMed 31917795
Targeting AXL and the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Melanoma
Mol Cancer Ther, 19 (3), 895-905
DOI 10.1158/1535-7163.MCT-19-0290, PubMed 31871265
MX 2 is a novel regulator of cell cycle in melanoma cells
Pigment Cell Melanoma Res, 33 (3), 446-457
DOI 10.1111/pcmr.12837, PubMed 31660681
A Three-dimensional Ex Vivo Viability Assay Reveals a Strong Correlation Between Response to Targeted Inhibitors and Mutation Status in Melanoma Lymph Node Metastases
Transl Oncol, 12 (7), 951-958
DOI 10.1016/j.tranon.2019.04.001, PubMed 31096111
p38 MAPK activation through B7-H3-mediated DUSP10 repression promotes chemoresistance
Sci Rep, 9 (1), 5839
DOI 10.1038/s41598-019-42303-w, PubMed 30967582
Soluble AXL is ubiquitously present in malignant serous effusions
Gynecol Oncol, 152 (2), 408-415
DOI 10.1016/j.ygyno.2018.11.012, PubMed 30448261
Expression, activation and clinical relevance of CHK1 and CHK2 in metastatic high-grade serous carcinoma
Gynecol Oncol, 150 (1), 136-142
DOI 10.1016/j.ygyno.2018.05.007, PubMed 29804637
Implementing precision cancer medicine in the public health services of Norway: the diagnostic infrastructure and a cost estimate
ESMO Open, 2 (2), e000158
DOI 10.1136/esmoopen-2017-000158, PubMed 28761742
hvTRA, a novel TRAIL receptor agonist, induces apoptosis and sustained growth retardation in melanoma
Cell Death Discov, 2, 16081
DOI 10.1038/cddiscovery.2016.81, PubMed 28028438
Expression and clinical significance of Wee1 in colorectal cancer
Tumour Biol, 37 (9), 12133-12140
DOI 10.1007/s13277-016-5081-3, PubMed 27220319
MiR-29a is a candidate biomarker of better survival in metastatic high-grade serous carcinoma
Hum Pathol, 54, 74-81
DOI 10.1016/j.humpath.2016.03.010, PubMed 27063471
Combined inhibition of the cell cycle related proteins Wee1 and Chk1/2 induces synergistic anti-cancer effect in melanoma
BMC Cancer, 15, 462
DOI 10.1186/s12885-015-1474-8, PubMed 26054341
Cellular localization of CIP2A determines its prognostic impact in superficial spreading and nodular melanoma
Cancer Med, 4 (6), 903-13
DOI 10.1002/cam4.425, PubMed 25663244
Wee1 is a novel independent prognostic marker of poor survival in post-chemotherapy ovarian carcinoma effusions
Gynecol Oncol, 135 (1), 118-24
DOI 10.1016/j.ygyno.2014.07.102, PubMed 25093290
High expression of wee1 is associated with malignancy in vulvar squamous cell carcinoma patients
BMC Cancer, 13, 288
DOI 10.1186/1471-2407-13-288, PubMed 23767999
Proton magnetic resonance metabolomic characterization of ovarian serous carcinoma effusions: chemotherapy-related effects and comparison with malignant mesothelioma and breast carcinoma
Hum Pathol, 44 (9), 1859-66
DOI 10.1016/j.humpath.2013.02.009, PubMed 23656974
Immunotoxin targeting EpCAM effectively inhibits peritoneal tumor growth in experimental models of mucinous peritoneal surface malignancies
Int J Cancer, 133 (6), 1497-506
DOI 10.1002/ijc.28158, PubMed 23494569
Low-dose anisomycin sensitizes melanoma cells to TRAIL induced apoptosis
Cancer Biol Ther, 14 (2), 146-54
DOI 10.4161/cbt.22953, PubMed 23192275
Aurora B expression in metastatic effusions from advanced-stage ovarian serous carcinoma is predictive of intrinsic chemotherapy resistance
Hum Pathol, 44 (5), 777-85
DOI 10.1016/j.humpath.2012.08.002, PubMed 23114921
MGST1 expression in serous ovarian carcinoma differs at various anatomic sites, but is unrelated to chemoresistance or survival
Gynecol Oncol, 126 (3), 460-5
DOI 10.1016/j.ygyno.2012.05.029, PubMed 22652154
Predicting platinum resistance in primary advanced ovarian cancer patients with an in vitro resistance index
Cancer Chemother Pharmacol, 69 (5), 1307-14
DOI 10.1007/s00280-012-1835-9, PubMed 22302409
HMGA2 protein expression in ovarian serous carcinoma effusions, primary tumors, and solid metastases
Virchows Arch, 460 (5), 505-13
DOI 10.1007/s00428-012-1228-9, PubMed 22476403
Synthetic retinoid CD437 induces apoptosis and acts synergistically with TRAIL receptor-2 agonist in malignant melanoma
Biochem Biophys Res Commun, 420 (3), 516-22
DOI 10.1016/j.bbrc.2012.03.023, PubMed 22446330
Cytoplasmic BRMS1 expression in malignant melanoma is associated with increased disease-free survival
BMC Cancer, 12, 73
DOI 10.1186/1471-2407-12-73, PubMed 22356677
High expression of Wee1 is associated with poor disease-free survival in malignant melanoma: potential for targeted therapy
PLoS One, 7 (6), e38254
DOI 10.1371/journal.pone.0038254, PubMed 22719872
Dacarbazine and the agonistic TRAIL receptor-2 antibody lexatumumab induce synergistic anticancer effects in melanoma
PLoS One, 7 (9), e45492
DOI 10.1371/journal.pone.0045492, PubMed 23029050
Flow cytometric measurement of cellular FLICE-inhibitory protein (c-FLIP) in ovarian carcinoma effusions
Cytopathology, 22 (6), 373-82
DOI 10.1111/j.1365-2303.2011.00929.x, PubMed 22032542
Targeting inhibitor of apoptosis proteins in combination with dacarbazine or TRAIL in melanoma cells
Cancer Biol Ther, 12 (1), 47-58
DOI 10.4161/cbt.12.1.15714, PubMed 21508672
Class III β-tubulin expression in advanced-stage serous ovarian carcinoma effusions is associated with poor survival and primary chemoresistance
Hum Pathol, 42 (7), 1019-26
DOI 10.1016/j.humpath.2010.10.025, PubMed 21315408
Overexpression of CDC25B, CDC25C and phospho-CDC25C (Ser216) in vulvar squamous cell carcinomas are associated with malignant features and aggressive cancer phenotypes
BMC Cancer, 10, 233
DOI 10.1186/1471-2407-10-233, PubMed 20500813
Biological effects induced by insulin-like growth factor binding protein 3 (IGFBP-3) in malignant melanoma
Int J Cancer, 126 (2), 350-61
DOI 10.1002/ijc.24727, PubMed 19588500
Cleaved caspase-3 and nuclear factor-kappaB p65 are prognostic factors in metastatic serous ovarian carcinoma
Hum Pathol, 40 (6), 795-806
DOI 10.1016/j.humpath.2008.10.019, PubMed 19157506
Diagnostic and prognostic role of the insulin growth factor pathway members insulin-like growth factor-II and insulin-like growth factor binding protein-3 in serous effusions
Hum Pathol, 40 (4), 527-37
DOI 10.1016/j.humpath.2008.10.003, PubMed 19121847
Different expression and clinical role of S100A4 in serous ovarian carcinoma at different anatomic sites
Tumour Biol, 30 (1), 15-25
DOI 10.1159/000199447, PubMed 19194111
Fli-1 expression in malignant melanoma
Histol Histopathol, 23 (11), 1309-14
DOI 10.14670/HH-23.1309, PubMed 18785112
The fatty acid binding protein 7 (FABP7) is involved in proliferation and invasion of melanoma cells
BMC Cancer, 8, 276
DOI 10.1186/1471-2407-8-276, PubMed 18826602
Dipeptidyl peptidase IV expression in cancer and stromal cells of human esophageal squamous cell carcinomas, adenocarcinomas and squamous cell carcinoma cell lines
APMIS, 116 (9), 823-31
DOI 10.1111/j.1600-0463.2008.01029.x, PubMed 19024603
1,5-Disubstituted 1,2,3-triazoles as cis-restricted analogues of combretastatin A-4: Synthesis, molecular modeling and evaluation as cytotoxic agents and inhibitors of tubulin
Bioorg Med Chem, 16 (9), 4829-38
DOI 10.1016/j.bmc.2008.03.049, PubMed 18396050
Death receptor expression is associated with poor response to chemotherapy and shorter survival in metastatic ovarian carcinoma
Cancer, 112 (1), 84-93
DOI 10.1002/cncr.23140, PubMed 17985388
Seprase, dipeptidyl peptidase IV and urokinase-type plasminogen activator expression in dysplasia and invasive squamous cell carcinoma of the esophagus. A study of 229 cases from Anyang Tumor Hospital, Henan Province, China
Oncology, 75 (1-2), 49-59
DOI 10.1159/000151741, PubMed 18787344
FAP-alpha and uPA show different expression patterns in premalignant and malignant esophageal lesions
Ultrastruct Pathol, 32 (3), 89-96
DOI 10.1080/01913120802034934, PubMed 18570153
Expression and clinical role of DJ-1, a negative regulator of PTEN, in ovarian carcinoma
Hum Pathol, 39 (1), 87-95
DOI 10.1016/j.humpath.2007.05.014, PubMed 17949781
Low-molecular weight forms of cyclin E differentiate ovarian carcinoma from cells of mesothelial origin and are associated with poor survival in ovarian carcinoma
Cancer, 110 (6), 1264-71
DOI 10.1002/cncr.22918, PubMed 17647260
Survivin, a member of the inhibitors of apoptosis family, is down-regulated in breast carcinoma effusions
Am J Clin Pathol, 128 (3), 389-97
DOI 10.1309/E899BG1282M5D505, PubMed 17709312
Expression of inhibitor-of-apoptosis protein family members in malignant mesothelioma
Hum Pathol, 38 (7), 986-994
DOI 10.1016/j.humpath.2006.12.013, PubMed 17350081
Nuclear expression of survivin is associated with improved survival in metastatic ovarian carcinoma
Cancer, 109 (2), 228-38
DOI 10.1002/cncr.22426, PubMed 17167759
Pax-5 expression in nonhematopoietic tissues
Am J Clin Pathol, 126 (5), 798-804
DOI 10.1309/XEC7-JMW9-YRM7-4RNO, PubMed 17050077
Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from diffuse malignant peritoneal mesothelioma
Clin Cancer Res, 12 (20 Pt 1), 5944-50
DOI 10.1158/1078-0432.CCR-06-1059, PubMed 17062665
Activation of c-jun N-terminal kinase is associated with cell proliferation and shorter relapse-free period in superficial spreading malignant melanoma
Mod Pathol, 19 (11), 1446-55
DOI 10.1038/modpathol.3800662, PubMed 16951673
Expression of HLA-G in malignant mesothelioma and clinically aggressive breast carcinoma
Virchows Arch, 449 (1), 31-9
DOI 10.1007/s00428-005-0144-7, PubMed 16541284
Proteomic analysis of malignant ovarian cancer effusions as a tool for biologic and prognostic profiling
Clin Cancer Res, 12 (3 Pt 1), 791-9
DOI 10.1158/1078-0432.CCR-05-2516, PubMed 16467090
The AP-2gamma transcription factor is upregulated in advanced-stage ovarian carcinoma
Gynecol Oncol, 100 (3), 462-8
DOI 10.1016/j.ygyno.2005.09.022, PubMed 16216317
Expression of activated Akt and PTEN in malignant melanomas: relationship with clinical outcome
Am J Clin Pathol, 124 (4), 528-36
DOI 10.1309/YT58WWMTA6YR1PRV, PubMed 16146807
Variation in gene expression patterns in effusions and primary tumors from serous ovarian cancer patients
Mol Cancer, 4, 26
DOI 10.1186/1476-4598-4-26, PubMed 16042759
Phorbol ester phorbol-12-myristate-13-acetate promotes anchorage-independent growth and survival of melanomas through MEK-independent activation of ERK1/2
Biochem Biophys Res Commun, 329 (1), 266-74
DOI 10.1016/j.bbrc.2005.01.143, PubMed 15721302
Expression patterns of cell cycle components in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors
J Neuropathol Exp Neurol, 64 (1), 74-81
DOI 10.1093/jnen/64.1.74, PubMed 15715087
Ets-1 transcription factor is widely expressed in benign and malignant melanocytes and its expression has no significant association with prognosis
Mod Pathol, 17 (11), 1400-6
DOI 10.1038/modpathol.3800206, PubMed 15205685
Expression of activated TrkA protein in melanocytic tumors: relationship to cell proliferation and clinical outcome
Am J Clin Pathol, 122 (3), 412-20
DOI 10.1309/CHFH-EYAT-44WW-P7J3, PubMed 15362372
Expression of S100A4 combined with reduced E-cadherin expression predicts patient outcome in malignant melanoma
Mod Pathol, 17 (8), 990-7
DOI 10.1038/modpathol.3800151, PubMed 15133476
Deacetylase inhibition in malignant melanomas: impact on cell cycle regulation and survival
Melanoma Res, 14 (3), 173-81
DOI 10.1097/01.cmr.0000129576.49313.26, PubMed 15179185
Granulin-epithelin precursor is a novel prognostic marker in epithelial ovarian carcinoma
Cancer, 100 (10), 2139-47
DOI 10.1002/cncr.20219, PubMed 15139056
Expression of the nerve growth factor receptors TrkA and p75 in malignant mesothelioma
Lung Cancer, 44 (2), 159-65
DOI 10.1016/j.lungcan.2003.11.014, PubMed 15084380
COX-2 expression in striated muscle under physiological conditions
Oral Dis, 9 (6), 313-6
DOI 10.1034/j.1601-0825.2003.00957.x, PubMed 14629333
Expression of activated extracellular signal-regulated kinases 1/2 in malignant melanomas: relationship with clinical outcome
Clin Cancer Res, 9 (14), 5325-31
PubMed 14614017
Reduced beta-catenin expression in the cytoplasm of advanced-stage superficial spreading malignant melanoma
Clin Cancer Res, 9 (9), 3383-8
PubMed 12960126
Expression and activation of the nerve growth factor receptor TrkA in serous ovarian carcinoma
Clin Cancer Res, 9 (6), 2248-59
PubMed 12796393
Candidate genes for testicular cancer evaluated by in situ protein expression analyses on tissue microarrays
Neoplasia, 5 (5), 397-404
DOI 10.1016/s1476-5586(03)80042-8, PubMed 14670177
Positional cloning identifies a novel cyclophilin as a candidate amplified oncogene in 1q21
Oncogene, 21 (14), 2261-9
DOI 10.1038/sj.onc.1205339, PubMed 11948409
Clinical and cell line specific expression profiles of a human gene identified in experimental central nervous system metastases
Anticancer Res, 22 (4), 1949-57
PubMed 12174869
Cyclin A expression in superficial spreading malignant melanomas correlates with clinical outcome
J Pathol, 195 (5), 530-6
DOI 10.1002/path.1007, PubMed 11745687
Expression of cell cycle proteins in ovarian carcinoma cells in serous effusions-biological and prognostic implications
Gynecol Oncol, 83 (2), 249-56
DOI 10.1006/gyno.2001.6388, PubMed 11606079
Amplification and overexpression of PRUNE in human sarcomas and breast carcinomas-a possible mechanism for altering the nm23-H1 activity
Oncogene, 20 (47), 6881-90
DOI 10.1038/sj.onc.1204874, PubMed 11687967
Reduced expression of p21WAF1 is an indicator of malignant behaviour in anal carcinomas
Histopathology, 39 (1), 43-9
DOI 10.1046/j.1365-2559.2001.01161.x, PubMed 11454043
Levels of cyclin D1 and D3 in malignant melanoma: deregulated cyclin D3 expression is associated with poor clinical outcome in superficial melanoma
Clin Cancer Res, 6 (9), 3614-20
PubMed 10999753
Up-regulation of ephrin-A1 during melanoma progression
Int J Cancer, 84 (5), 494-501
DOI 10.1002/(sici)1097-0215(19991022)84:5<494::aid-ijc8>3.0.co;2-o, PubMed 10502726
Collateral expression of proangiogenic and tumorigenic properties in intestinal epithelial cell variants selected for resistance to anoikis
Neoplasia, 1 (1), 23-30
DOI 10.1038/sj.neo.7900001, PubMed 10935467
Interleukin-6 dependent induction of the cyclin dependent kinase inhibitor p21WAF1/CIP1 is lost during progression of human malignant melanoma
Oncogene, 18 (4), 1023-32
DOI 10.1038/sj.onc.1202382, PubMed 10023678
E-Cadherin-dependent growth suppression is mediated by the cyclin-dependent kinase inhibitor p27(KIP1)
J Cell Biol, 142 (2), 557-71
DOI 10.1083/jcb.142.2.557, PubMed 9679152
Protein expression of the cell-cycle inhibitor p27Kip1 in malignant melanoma: inverse correlation with disease-free survival
Am J Pathol, 153 (1), 305-12
DOI 10.1016/S0002-9440(10)65572-1, PubMed 9665492
High levels of messenger RNAs for tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastases
Clin Cancer Res, 3 (9), 1623-8
PubMed 9815852
Differential expression patterns of S100A2, S100A4 and S100A6 during progression of human malignant melanoma
Int J Cancer, 74 (4), 464-9
DOI 10.1002/(sici)1097-0215(19970822)74:4<464::aid-ijc19>3.0.co;2-9, PubMed 9291441
Loss of expression of receptor tyrosine kinase family genes PTK7 and SEK in metastatic melanoma
Int J Cancer, 71 (6), 1061-5
DOI 10.1002/(sici)1097-0215(19970611)71:6<1061::aid-ijc24>3.0.co;2-f, PubMed 9185712
Expression of stromelysin-3 in medullary carcinoma of the breast
Anticancer Res, 17 (5B), 3725-7
PubMed 9427769
TGF-beta mediated G1 arrest in a human melanoma cell line lacking p15INK4B: evidence for cooperation between p21Cip1/WAF1 and p27Kip1
Oncogene, 13 (11), 2447-57
PubMed 8957087
Reversal of the in vivo metastatic phenotype of human tumor cells by an anti-CAPL (mts1) ribozyme
Cancer Res, 56 (23), 5490-8
PubMed 8968106
Cyclin kinase inhibitor p21WAF1/CIP1 in malignant melanoma: reduced expression in metastatic lesions
Am J Pathol, 149 (6), 1813-22
PubMed 8952518
Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents
Nat Med, 2 (11), 1204-10
DOI 10.1038/nm1196-1204, PubMed 8898746
Involvement of the pRb/p16/cdk4/cyclin D1 pathway in the tumorigenesis of sporadic malignant melanomas
Br J Cancer, 73 (8), 909-16
DOI 10.1038/bjc.1996.181, PubMed 8611425
Homozygous deletion frequency and expression levels of the CDKN2 gene in human sarcomas--relationship to amplification and mRNA levels of CDK4 and CCND1
Br J Cancer, 72 (2), 393-8
DOI 10.1038/bjc.1995.344, PubMed 7640224
Accumulation of p53 protein in human malignant melanoma. Relationship to clinical outcome
Melanoma Res, 5 (3), 183-7
DOI 10.1097/00008390-199506000-00007, PubMed 7640520
In vitro and in vivo variation in transferrin receptor expression on a human medulloblastoma cell line
Neurosurgery, 36 (6), 1158-63; discussion 1163-4
DOI 10.1227/00006123-199506000-00015, PubMed 7643997
The protooncogene CHOP/GADD153, involved in growth arrest and DNA damage response, is amplified in a subset of human sarcomas
Cancer Genet Cytogenet, 78 (2), 165-71
DOI 10.1016/0165-4608(94)90085-x, PubMed 7828148
MDM2 gene amplification and transcript levels in human sarcomas: relationship to TP53 gene status
J Natl Cancer Inst, 86 (17), 1297-302
DOI 10.1093/jnci/86.17.1297, PubMed 8064888
TP53 allele loss, mutations and expression in malignant melanoma
Br J Cancer, 69 (2), 253-9
DOI 10.1038/bjc.1994.48, PubMed 7905277
Mapping of amplification units in the q13-14 region of chromosome 12 in human sarcomas: some amplica do not include MDM2
Cell Growth Differ, 4 (12), 1065-70
PubMed 8117620
Review articles
Induction and reversal of cell adhesion-dependent multicellular drug resistance in solid breast tumors
Hum Cell, 9 (4), 257-64
PubMed 9183656
Other articles
Suppression of the neoplastic phenotype in vivo by an anti-ras ribozyme
Cancer Res, 54 (4), 900-2
PubMed 8313379
Expression of the neuroectodermal intermediate filament nestin in human melanomas
Cancer Res, 54 (2), 354-6
PubMed 8275467
p53 abnormalities in different subtypes of human sarcomas
Cancer Res, 53 (3), 468-71
PubMed 8425179
Levels of nm23 messenger RNA in metastatic malignant melanomas: inverse correlation to disease progression
Cancer Res, 52 (21), 6088-91
PubMed 1356624
Theses
Molecular studies of factors putatively implicated in thedevelopment, progression and metastasis of malignant melanomaand sarcoma
Norwegian Cancer Society : Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, [Oslo], 1 b. (flere pag.)
BIBSYS 950166472, ISBN 82-7633-050-9
Sammenheng mellom syntese av poly(ADP-ribose), DNA skaderog reparasjon i Ehrlich ascites tumor celler alkylert med N-metyl-N-nitrosourea (MNU), N-metyl-N`-nitro-N-nitrosoguandin (MNNG) og metyl metansulfonat
V.A. Flørenes, Oslo, 102 s.
BIBSYS 961328703